Reviewing Curis (CRIS) & WAVE Life Sciences (WVE)

Curis (NASDAQ: CRIS) and WAVE Life Sciences (NASDAQ:WVE) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.

Analyst Ratings

This is a summary of current ratings and recommmendations for Curis and WAVE Life Sciences, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Curis 0 0 3 0 3.00
WAVE Life Sciences 0 0 5 0 3.00

Curis currently has a consensus price target of $6.50, indicating a potential upside of 647.13%. WAVE Life Sciences has a consensus price target of $41.60, indicating a potential upside of 5.72%. Given Curis’ higher possible upside, equities research analysts plainly believe Curis is more favorable than WAVE Life Sciences.

Profitability

This table compares Curis and WAVE Life Sciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Curis -629.29% -250.58% -81.57%
WAVE Life Sciences -3,338.68% -59.52% -48.48%

Risk & Volatility

Curis has a beta of 1.63, meaning that its stock price is 63% more volatile than the S&P 500. Comparatively, WAVE Life Sciences has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500.

Institutional & Insider Ownership

55.2% of Curis shares are held by institutional investors. Comparatively, 73.7% of WAVE Life Sciences shares are held by institutional investors. 4.1% of Curis shares are held by insiders. Comparatively, 53.0% of WAVE Life Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Curis and WAVE Life Sciences’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Curis $7.53 million 18.95 -$60.41 million ($0.40) -2.18
WAVE Life Sciences $1.49 million 733.92 -$55.40 million ($3.54) -11.12

WAVE Life Sciences has lower revenue, but higher earnings than Curis. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.

Summary

WAVE Life Sciences beats Curis on 7 of the 12 factors compared between the two stocks.

About Curis

Curis, Inc. is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target programmed death ligand-1 (PDL1) and V-domain Ig suppressor of T-cell activation (VISTA) immune checkpoint proteins, both of which independently function as negative regulators of immune activation. CA-4948 is an oral small molecule drug candidate that is designed to inhibit the Interleukin-1 receptor-associated kinase 4 (IRAK4) kinase, which is a transducer of toll-like receptor or certain interleukin receptor signaling pathways.

About WAVE Life Sciences

WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. The nucleic acid therapeutics, which the Company is developing are stereopure. A stereopure oligonucleotide includes molecules with atoms arranged in three-dimensional orientations at each linkage. The Company has three programs in Huntington’s disease (HD) and Duchenne Muscular Dystrophy (DMD), and three additional development candidates.

What are top analysts saying about Curis Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Curis Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit